Viscum Album for TNBC on Adjuvant Pembrolizumab

The goal of this clinical trial is to evaluate the efficacy and safety of Viscum album extract when used in combination with pembrolizumab as adjuvant chemotherapy in adult patients (aged 19 and older) who have been diagnosed with malignant neoplasm of unilateral breast and have completed surgery. The main questions it aims to answer are: Does the addition of Viscum album improve clinical outcomes when combined with pembrolizumab as adjuvant chemotherapy? Is Viscum album safe and tolerable for use in this patient population?

Trial Details

NCT ID
NCT06920810
Phase
PHASE4
Sponsor
Ilsan Cha hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • viscum album
Locations (sample)
  • Goyang-si, Gyeonggi-do, South Korea|37.65639,126.835

Key Eligibility Criteria

  • Adults aged 19 years or older
  • Histologically confirmed diagnosis of triple-negative breast cancer
  • ECOG Performance Status of 0 or 1
  • Completed surgery and radiotherapy for localized disease, and either (a) requires adjuvant chemotherapy including immune checkpoint inhibitors, or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →